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SCIENCE FOR JUDGES VIII: 
INTRODUCTION 
Margaret A. Berger*
The Journal of Law and Policy is once again publishing 
extended versions of presentations made by speakers at a 
conference for federal and state judges on science and the law.1 
The conference, which took place at Brooklyn Law School on 
November 3 and 4, 2006, was the eighth in a series of Science 
for Judges programs funded by the Common Benefit Trust 
established in the Silicone Breast Implant Products Liability 
Litigation. It was held under the auspices of Brooklyn Law 
School’s Center for Health, Science and Public Policy in 
collaboration with the Federal Judicial Center, the National 
Center for State Courts, and the Committee on Science, 
Technology and Law of the National Academies of Science. 
 * Suzanne J. and Norman Miles Professor of Law, Brooklyn Law 
School. Professor Berger is the Director of the Science for Judges Program. 
1 Papers from previous Science for Judges programs can be found at 12 
J.L. & POL’Y 1, 1-53 (2003) (papers discussing the practice of epidemiology 
and the science produced by administrative agencies); 12 J.L. & POL’Y 485, 
485, 485-639 (2004) (papers discussing toxicology and epidemiology); 13 
J.L. & POL’Y 1, 1-179 (2005) (papers discussing the integrity of scientific 
research and forensic evidence in criminal proceedings); 13 J.L. & POL’Y 
499, 499-647 (2005) (papers discussing Agent Orange and human behavior 
research); and 14 J.L. & POL’Y 1, 1-209 (2006) (papers discussing risk 
assessment dealing with expert proof of causation in toxic tort cases and 
issues relevant to the availability of data); 14 J.L. & POL’Y 525, 525-616 
(2006) (papers discussing evidence-based medicine); 15 J.L. & POL’Y 1, 1-
164 (2007) (papers discussing the evidence of causation as well as current 
issues and standards of forensic laboratories). All papers are available in 
electronic form at http://brooklaw.edu/centers/scienceforjudges/papers.php. 
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This time, the program focused on pharmaceutical drugs and 
asbestos, two products whose use—past and present—raises 
troublesome issues for the American legal system. From a 
scientific perspective as well, the questions posed are complex 
and costly. In addition to their potent impact on public health 
and the litigation process, the issues surrounding 
pharmaceuticals and asbestos affect not only the courts but also 
congress and administrative agencies. The articles that follow 
view the resulting problems in a variety of different contexts that 
illustrate the myriad challenges and possible solutions that arise 
at the intersection of science and the law. An added bonus is 
that two of the papers provide us with a glimpse of how other 
legal systems react. Furthermore, these articles are extremely 
timely; they deal with current problems some of which may 
have received more coverage on the web than in law reviews. 
The first article, by Dr. Drummond Rennie, looks at the 
pharmaceutical industry from the vantage point of a professor of 
medicine and a medical editor, who has worked at the two most 
prestigious general medical journals.2 Dr. Rennie tells a 
sobering tale of how a changing academic culture led to 
enormous conflicts of interest once the Baye-Dole Act’s passage 
in 1980, allowed universities to profit from scientific 
discoveries.3 The consequence, according to Dr. Rennie, has 
been research misconduct, the biased reporting of results, the 
burying of negative results, and the publishing of trials that 
ostensibly come from research universities but are actually 
produced by the companies sponsoring the studies. He also 
discusses changes at the FDA that have made it far more 
company-friendly. He offers numerous suggestions for what 
must be done in order for the pharmaceutical companies and the 
FDA to regain our trust. Dr. Rennie clearly believes that our 
present system—as formally constituted and implemented—does 
not adequately safeguard the public’s health. 
The next article by Professor Catherine Sharkey views the 
2 Drummond Rennie, When Evidence Isn’t: Trials, Drug Companies and 
the FDA, 15 J.L. & POL’Y 991 (2007). 
3 Id. at 997. 
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problem of pharmaceuticals from a very different perspective.4 
Even while the FDA was embroiled in a number of controversial 
cases,5 that led to its requesting a review by a committee of the 
National Academies’ Institute of Medicine which has now 
published a highly critical report,6 the FDA was issuing a new 
rule for labeling prescription drugs. In the preamble to the new 
rule the FDA stated its view that the rule preempted competing 
state law regulatory and common law claims.7
Professor Sharkey’s article examines the history of the 
preemption doctrine in the products liability realm in general, 
considers differences in the response of federal and state courts, 
and discusses the abandonment of the regulatory compliance 
defense in favor of the federal preemption doctrine. She then 
turns to the 2006 preemption claim by the FDA and analyzes the 
federal and state cases that have dealt with the issue. She finds, 
not surprisingly, that the federal courts have been more 
receptive to the FDA’s position. Preemption is obviously a 
highly complex issue that implicates federalism concerns as well 
as the operation of deference to interpretations by administrative 
agencies. Although it is far too soon to know what the ultimate 
fate of the preemption defense will be, and its impact on toxic 
tort litigation involving pharmaceuticals, it seems safe to predict 
that Professor Sharkey’s article will be the starting point for 
many discussions of this problem. 
Professor Anita Bernstein’s article proceeds on a completely 
different track.8 Although she notes that pharmaceutical 
4 Catherine M. Sharkey, Federalism in Action: FDA Regulatory 
Preemption in Pharmaceutical Cases In State Versus Federal Courts, J.L. & 
POL’Y 1051 (2007). 
5 RENNIE, supra note 2, at 1003-006. 
6 Institute of Medicine, Committee on the Assessment of the US Drug 
Safety System, The Future of Drug Safety: Promoting and Protecting the 
Health of the Public (Anita Baciu, et al eds., National Academies Press, 
2007). 
7 Requirements on Content and Format of Labeling for Human 
Prescription Drug and Biological Products, 71 Fed. Reg. 3922, 3934, n. 7 
(Jan 24, 2006) (effective date June 30, 2006). 
8 Anita Bernstein, Enhancing Drug Effectiveness and Efficacy Through 
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companies have on the whole been affected very little by 
personal injury litigation, she is willing to assume that such 
litigation can cause harm to the drug industry and its customers. 
What Professor Bernstein seeks is a means by which prescription 
drug liability can play a positive role in improving the practices 
of the pharmaceutical industry. She makes the novel suggestion 
that courts consider “ineffectiveness” as an actionable injury 
instead of tying liability solely to a lack of safety. In Part I of 
her article she explores the meaning of effectiveness, including 
the difference between effectiveness and efficacy. Part II 
examines the harms caused to consumers by ineffective drugs 
that do not live up to promises on a label, and in Part III 
Professor Bernstein makes specific suggestions for modest first 
steps that courts could take when manufacturers make false 
promises. Her thesis promotes a fresh scrutiny of the 
pharmaceutical industry to determine whether the current system 
is in the public’s best interest, and asks that we reconsider the 
role of the tort system. 
The last article about pharmaceuticals by Robert Nakagawa, 
a member of the British Columbia Ministry of Health, discusses 
measures Canada has taken to reduce the price of prescription 
drugs.9 Each provincial government determines for which drugs 
they will provide payment. Safety and efficacy assessments enter 
into these determinations which British Columbia reaches by 
considering information generated by its extensive database 
which currently includes all prescriptions dispensed within 
province’s pharmacies since 1995. The extensive database also 
operates to detect fraud and to identify emerging problems, such 
as harmful interactions caused by taking more than one drug. 
Many of the problems discussed in the preceding articles on 
pharmaceuticals could undoubtedly be avoided in the United 
States if more information were available on how the 
prescription drugs on the American market actually work. 
The articles on asbestos are equally rich. It may surprise 
Personal Injury Litigation, 15 J.L. & POL’Y 1051 (2007). 
9 Robert S. Nakagawa, Prescription Drug Systems and Price Control in 
Canada, 15 J.L. & POL’Y 1103 (2007). 
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some that more than fifty years after exposure to asbestos fibers 
was linked to cancers of the respiratory tract, and more than 
thirty years after asbestos litigation began, unresolved questions 
remained about asbestos and the causation of non-respiratory 
cancers. Dr. Jonathan Samet writes about the Institute of 
Medicine Committee he chaired which Congress charged with 
carrying out a study on the association of asbestos with 
colorectal, laryngeal, oropharyngeal, stomach, and esophageal 
cancers.10 Dr. Samet’s discussion of the methodology used by 
the Committee, the reasons for uncertainties that remain, the 
classification system adopted by the Committee, and the 
Committee’s findings will be of interest not only to those who 
deal with asbestos, but to all concerned with issues of causation 
from the legal or scientific perspective. As causation is the 
crucial problem in virtually all toxic tort litigation, this essay 
should attract many readers in a variety of disciplines. 
The next article by Patrick Hanlon, which discusses the 
attempt to handle asbestos claims through federal legislation,11 is 
related to the previous article by Dr. Samet. Congress had 
commissioned the Institute of Medicine study, because the 
information sought was needed to implement a congressional 
compensation scheme. Ultimately, as Mr. Hanlon relates, the 
proposed FAIR Act failed to pass. His explanation of the 
provisions in the bill, the numerous complex scientific questions 
that had to be addressed, and the policy issues that could not be 
resolved make fascinating reading. This is an article about 
science, law and politics. The descriptions of the various 
constituencies that had a stake in the bill and their reactions 
suggest that legislation may never be a viable option for 
reforming toxic tort litigation. In that case, of course, most 
decision-making will be left to the courts. Fortunately, the 
number of new asbestos claims has decreased dramatically for 
10 Jonathan M. Samet, Asbestos and Causation of Non-Respiratory 
Cancers: Evaluation by the Institute of Medicine, 15 J.L. & POL’Y 1117 
(2007). 
11 Patrick M. Hanlon, Federal Asbestos Legislation: Wrestling with the 
Medical Issues, 15 J.L. & POL’Y 1171 (2007). 
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reasons also explored by Mr. Hanlon. 
David Michaels and Celeste Monforton examine instances in 
which the scientific literature on asbestos has been skewed by 
litigation generated science.12 Looking almost exclusively at the 
literature on auto mechanics’ exposure to asbestos in friction 
products, Michaels and Monforton could find only one new 
epidemiological study on disease risk for auto mechanics in the 
ten years following the Occupational Safety and Health 
Administration’s (“OSHA”) final asbestos standard.13 
Nevertheless, 39 papers have been published that do not contain 
new scientific data. Of these, the authors identified 26 as 
litigation-generated papers which offer literature reviews and 
reanalyze in a manner that would be useful for litigation. 
Michaels and Monforton conclude that the result is that 
whichever side pays more has more papers published. What 
looks like a consensus in the scientific community is instead “an 
artifact of sponsorship.”14 At least as troubling is Michaels’ and 
Montforton’s charge that government agencies like the 
Environmental Protection Agency (“EPA”) and OSHA have 
been pressured to remove valuable information from publications 
that linked asbestos exposure to disease in auto mechanics. 
The last paper on asbestos litigation in New South Wales, 
Australia, was submitted by Judge Lawrence O’Meally, the 
President of the Dust Diseases Tribunal of New South Wales.15 
Australia apparently has an incidence of malignant 
mesothelioma—an asbestos signature disease—that is higher than 
that of any other country. Until the Tribunal was established, 
some claimants died before their claims were heard in court. 
Since 1989, these claims are now handled on an expedited basis 
12 David Michaels & Celeste Monforton, How Litigations Shapes the 
Scientific Literature: Asbestos and Disease Among Auto Mechanics, 15 J.L. 
& POL’Y 1127 (2007). 
13 The reasons for why new research has not been done are explored id. 
at 1157-161. 
14 Id. at 1166. 
 15 Hon. John Lawrence O’Meally, Asbestos Litigation In New South 
Wales, J.L. & POL’Y 1209 (2007). 
 
BERGER INTRO.DOC 7/1/2007 10:41 PM 
 SCIENCE FOR JUDGES VIII 989 
                                                          
before the Tribunal, which is a parallel court system in which all 
cases are tried before a judge. All cases are subject to 
compulsory mediation. Judge O’Meally’s paper examines some 
of the other provisions of the Act. He makes the astonishing 
statement that in some cases less than four hours elapse between 
the filing of a statement of claim and the conclusion of the 
case.16
The articles based on the eighth Science for Judges program 
illuminate how difficult it is to resolve issues relating to 
pharmaceuticals and asbestos. On top of the ordinary 
complexities posed when science and the law intersect are 
problems such as the conflicts of interest and unethical behavior 
attributable to the enormous sums at stake, political pressures, 
unsettled issues about federalism, and uncertainties about the 
appropriate role of administrative agencies and congress. New 
and better solutions are definitely needed, but these articles spell 
out the enormous obstacles that have to be overcome. 
 16 Id. at 1215. 
